The darlings of the weight loss and diabetes spaces, GLP-1 receptor agonists have shown promise against Alzheimer’s in recent studies—with Phase III results expected next year from Novo Nordisk.
Carol BaldwinLocal Journalism Initiative ReporterWakaw RecorderAfter the heavy snowfall, and a drop in temperature across the province, interrupted by a bri ...